Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Is it the right time to enter pharma stocks?

      The pharma sector has seen the biggest correction over the past one month. The index itself has seen a 5 percent fall from the top. Abhishek Sharma, a pharma analyst at IIFL, gave his views on Dr Reddy's, Glenmark, Cipla and Sun Pharma.

    • Like private banks, selective pharma, TCS, Infosys: Angel

      Mayuresh Joshi of Angel Broking likes private banks and selective pharma names and also likes TCS, Infosys and HCL Technologies.

    • Look at pharma stocks: TS Harihar

      TS Harihar of HRBV Client Solutions is of the view that one may look at the pharma space once the market stabilises around 7,400-7,500.

    • Add HDFC Bank, ICICI Bank, SBI, TCS: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can add HDFC Bank, ICICI Bank, SBI and TCS in the portfolio.

    • Buy Lupin, Sun Pharma, Dr Reddy's at lower levels: Baliga

      According to Ambareesh Baliga, Independent Market Expert, one can buy Lupin, Sun Pharma and Dr Reddy's Labs at lower levels.

    • See pressure in pharma space: Sahil Kapoor

      According to Sahil Kapoor of Edelweiss Financial Services, one may see pressure in the pharma space.

    • Prefer IT, pharma stocks: Ajay Bagga

      Ajay Bagga, Market Expert is of the view that one may prefer IT and pharma stocks.

    • Metals short selling idea; prefer pharma, IT, OMCs: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that metal stocks are short selling ideas and prefers private sector banks, pharmaceuticals, IT, Reliance Industries and oil marketing companies.

    • Pick Sun Pharma, says Sudip Bandopadhyay

      Sudip Bandopadhyay, President at Destimoney Securities is of the view that one can pick Sun Pharma at the current level.

    • Prefer Dishman Pharma, Sun Pharma: Mayuresh Joshi

      Mayuresh Joshi of Angel Broking is of the view that one may prefer Dishman Pharma and Sun Pharma from the pharma space.

    • CLSA retains buy on Sun Pharma; sees 40% FY17 EBITDA growth

      According to the brokerage, India & core US businesses and generic Gleevec launch are critical to drive its FY17 EBITDA (earnings before interest, tax, depreciation and amortisation). It expects 40 percent Y-o-Y FY17 EBITDA growth for Sun Pharma.

    • Prefer HDFC Bank, ICICI Bank, SBI, Sun Pharma: Dilip Bhat

      Dilip Bhat of Prabhudas Lilladher is of the view that one may prefer HDFC Bank, ICICI Bank and SBI for long term.

    • Prefer IT, pharma space: Siddarth Bhamre

      Siddarth Bhamre of Angel Broking is of the view that one may prefer the IT and the pharma space.

    • Prefer Sun Pharma, Dishman Pharmaceuticals: Mayuresh Joshi

      Mayuresh Joshi of Angel Broking is of the view that one can prefer Sun Pharma and Dishman Pharmaceuticals.

    • Buy Infosys, Sun Pharma, SBI, ICICI Bank, HDFC: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Infosys, Sun Pharmaceutical Industries, State Bank of India, ICICI Bank, HDFC and Aurobindo Pharma.

    • Buy IT, pharma stocks on dips: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying IT and pharma stocks on dips.

    • Prefer pharma, IT stocks: Rahul Mohindar

      Rahul Mohindar of viratechindia.com is of the view that one may prefer pharmaceuticals and technology stocks looking at the buy side of the market.

    • Look at pharma, private banks, IT: Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that one may look at pharmaceutical, private sector banks and the IT space.

    • Like Sun Pharma, Strides Arcolab: Deepak Shenoy

      Deepak Shenoy, Founder of Capitalmind.in likes Sun Pharma and Strides Arcolab and feels that pharma as a space is worth looking into.

    • Look at auto, pharma space: Sudip Bandopadhyay

      Sudip Bandopadhyay of Destimoney Securities is of the view that one can look at buying the automobile and pharma stocks.

    • Invest in Infosys, SBI, Maruti, Sun Pharma, L&T: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can consider investing in Infosys, State Bank of India, ICICI Bank, Sun Pharmaceutical Industries, Maruti Suzuki, Larsen and Toubro, Housing Development Finance Corporation and Aurobindo Pharma.

    • Positive on pharma, IT sectors: Hemindra Hazari

      Hemindra Hazari, Independent Market Expert has a positive view on the IT and pharma sectors.

    • Buy Infosys, Sun Pharma, Zee Entertainment: Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Infosys, Sun Pharmaceutical Industries and Zee Entertainment Enterprises.

    • Check Out: Super Six stocks for August 21

      Jay Thakkar of ShareKhan suggests selling Axis Bank with a target of Rs 490.

    • Like Divis Laboratories, Torrent Pharma: Anmol Ganjoo

      Anmol Ganjoo of JM Financial likes Divis Laboratories and Torrent Pharma from the pharma space.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347